Jill Corre

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 953 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Immunomodulatory effect of human adipose tissue‐derived adult stem cells: comparison with bone marrow mesenchymal stem cells

Bénédicte Puissant‐Lubrano, Corinne Barreau, Philippe Bourin et al. · British Journal of Haematology · 2005 · 943 citations

Life Sciences, Cell Biology, Immunology +17

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Aurore Perrot, Valérie Lauwers‐Cancès, Jill Corre et al. · Blood · 2018 · 420 citations · Full text

Medicine, Hematology, Oncology +15

Bone marrow mesenchymal stem cells are abnormal in multiple myeloma

Jill Corre, Karène Mahtouk, Michel Attal et al. · Leukemia · 2007 · 321 citations · Full text

Medicine, Cell Biology, Hematology +14

Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome

Murielle Roussel, Valérie Lauwers‐Cancès, Nelly Robillard et al. · Journal of Clinical Oncology · 2014 · 265 citations · Full text

Medicine, Oncology, Pharmacotherapy +14